Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Jun 30, 2026
Eli Lilly emerges as the frontrunner in the weight-loss and diabetes drug race, yet competitor Novo Nordisk isn't waving the white flag just yet. Discover the implications for investors and the broader market.